Skip to main content
Apply for Grants

Funding Opportunities

Thank you for your important research toward breakthroughs for people with Parkinson's and for your interest in working with The Michael J. Fox Foundation.

See below for our current open funding program. We will launch more RFAs in November.

Email grants@michaeljfox.org with questions.

Please review our FAQs for guidance on COVID-19 and research support. 

Browse Funding Opportunities

Open Programs

  • The Edmond J. Safra Fellowship in Movement Disorders
    Objective:
    The Edmond J. Safra Fellowship in Movement Disorders aims to grow the global base of movement disorder specialists — neurologists with additional training in Parkinson's disease and other movement disorders — by training movement disorder clinician-researchers who can provide expert care and lead scientific advances.

Programs in Review

  • ASAP Collaborative Research Network: Circuitry and Brain-body Interactions
    ASAP logo
    Objective:
    The ASAP Collaborative Research Network, a program of the Aligning Science Across Parkinson’s (ASAP) initiative being implemented through The Michael J. Fox Foundation, seeks to support multidisciplinary, multi-institutional research teams to address key knowledge gaps in the basic mechanisms that contribute to Parkinson’s development and progression.
  • Promoting Diversity, Equity and Inclusion in Parkinson’s Disease Research
    Objective:
    The Michael J. Fox Foundation seeks applications with the potential to increase knowledge about Parkinson’s disease in populations that have been excluded from or underrepresented in research.
  • Alpha-synuclein Seed Amplification Assay Program
    Objective:
    This program supports research that will facilitate integration of alpha-synuclein seed amplification assays into clinical studies for the purposes of predicting prognosis, tracking disease progression and monitoring therapeutic response.
  • Therapeutic Pipeline Program: Pre-clinical Studies
    Objective:
    This funding program — an Edmond J. Safra Core Program for PD Research — will support development of Parkinson’s disease (PD) therapeutics with potential for fundamentally altering disease course or significantly improving non-motor or motor symptoms.
  • Target Advancement: Tool Generation and Target Validation
    Objective:
    This funding program — an Edmond J. Safra Core Program for PD Research — seeks to build conclusive evidence and develop field-enabling tools around early-stage biological targets in Parkinson’s disease (PD).
  • Cellular Phenotyping in Human iPSCs
    Objective:
    This program will support phenotyping of human induced pluripotent stem cells (iPSCs) from our Parkinson’s Progression Markers Initiative (PPMI). Such work will facilitate future mechanistic studies and expedite drug screening and proof-of-concept testing for Parkinson’s therapeutics.
  • Parkinson’s Pathway Molecular Data Analysis
    Objective:
    This funding program will support high-impact projects that utilize existing data resources to increase molecular understanding of Parkinson’s disease (PD), correlate biological changes to clinical/other outcomes, and more deeply interrogate disrupted pathways in PD.
  • MRI Biomarkers: Data Analysis and Tool Generation
    Objective:
    This funding program will support studies to develop reproducible diagnostic, prognostic, and monitoring magnetic resonance imaging (MRI) biomarkers.

Closed Programs

  • Therapeutic Pipeline Program
    Objective:
    The Michael J. Fox Foundation funds work with potential for fundamentally altering disease course and/or significantly improving treatment of symptoms above and beyond current standards of care.
  • Target Advancement Program
    Objective:
    The Michael J. Fox Foundation funds work that leverages and translates basic research to enable therapeutic development.
  • Development and Validation of Improved Outcome Measures
    Objective:
    This program funds work to develop objective biomarkers that can support therapeutic development in Parkinson’s.
  • Analysis of Patient-Reported Outcomes from Fox Insight
    Objective:
    This program funds analyses of the patient-reported outcomes (PROs) and genetic data collected through the Fox Insight study.
  • PIPETTE: 4R Tau and Alpha-Synuclein PET Tracer Development
    Objective:
    The PIPETTE Consortium (Philanthropic Investments in PET TracErs) is a funding partnership formed in 2017 by The Michael J. Fox Foundation and Rainwater Charitable Foundation (conveners of the Tau Consortium).
  • Investigating Environmental Factors that Increase the Risk for Parkinson’s Disease
    Objective:
    This funding program supported projects to investigate environmental exposures, such as chemicals or toxic emissions, that increase the risk of PD and/or influence disease progression.
  • Parkinson’s Pathway Biomarkers
    Objective:
    The Michael J. Fox Foundation seeks applications with the potential to develop new/better biomarkers for measuring pathway function or dysfunction that can support therapeutic development for affected pathways in Parkinson’s disease (PD).
  • Ken Griffin Alpha-synuclein Imaging Competition
    Ken Griffin Alpha-synuclein Imaging Competition Logo
    Objective:
    The Michael J. Fox Foundation has prioritized alpha-synuclein imaging as the most likely imaging approach to have an impact for therapeutic development. The goal of this $10-million funding program is to deliver a selective alpha-synuclein PET tracer for use in clinical studies.
  • Illustrated avatar with check mark.

    Grant Portal

    View submitted or in progress applications.

  • Illustrated envelope containing alert message.

    Funding Alerts

    Sign up for email updates on resources and initiatives to accelerate research and improve Parkinson's care.

  • Illustrated series of test tubes.

    Application Guidelines

    Our funding application guidelines cover our review process and criteria, confidentiality, conflicts of interest, and special requirements. 

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.